Notice2021-19437
Reconsidering Mandatory Opioid Prescriber Education Through a Risk Evaluation and Mitigation Strategy in an Evolving Opioid Crisis; Public Workshop; Request for Comments
Primary source
Metadata and text below are from the Federal Register, a public-domain U.S. government work. Always verify the official published version before relying on it for any legal matter.
Published
September 9, 2021
Issuing agencies
Health and Human Services DepartmentFood and Drug Administration
Abstract
The Food and Drug Administration (FDA, the Agency, or we) is announcing the following public workshop entitled "Reconsidering Mandatory Opioid Prescriber Education Through a Risk Evaluation and Mitigation Strategy (REMS) in an Evolving Opioid Crisis." Convened by the Duke-Margolis Center for Health Policy and supported by a cooperative agreement between FDA and Duke-Margolis, the purpose of the public workshop is to give stakeholders an opportunity to provide input on aspects of the current opioid crisis that could be mitigated in a measurable way by requiring mandatory prescriber education as part of a REMS. We expect interested stakeholders to include healthcare providers, healthcare professional associations, pharmacists, pharmacy benefit managers, public and private insurers, patient organizations, Federal and State Agencies, providers of continuing education for healthcare professionals, and the public. A second public workshop is being planned to solicit input on additional issues associated with a move to mandatory prescriber education under a REMS, such as operational and technical issues related to such a system and what should be included in potential mandatory prescriber education.
Full Text
<html>
<head>
<title>Federal Register, Volume 86 Issue 172 (Thursday, September 9, 2021)</title>
</head>
<body><pre>
[Federal Register Volume 86, Number 172 (Thursday, September 9, 2021)]
[Notices]
[Pages 50541-50543]
From the Federal Register Online via the Government Publishing Office [<a href="http://www.gpo.gov">www.gpo.gov</a>]
[FR Doc No: 2021-19437]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA-2021-N-0951]
Reconsidering Mandatory Opioid Prescriber Education Through a
Risk Evaluation and Mitigation Strategy in an Evolving Opioid Crisis;
Public Workshop; Request for Comments
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice of public workshop; request for comments.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA, the Agency, or we) is
announcing the following public workshop entitled ``Reconsidering
Mandatory Opioid Prescriber Education Through a Risk Evaluation and
Mitigation Strategy (REMS) in an Evolving Opioid Crisis.'' Convened by
the Duke-Margolis Center for Health Policy and supported by a
cooperative agreement between FDA and Duke-Margolis, the purpose of the
public workshop is to give stakeholders an opportunity to provide input
on aspects of the current opioid crisis that could be mitigated in a
measurable way by requiring mandatory prescriber education as part of a
REMS. We expect interested stakeholders to include healthcare
providers, healthcare professional associations, pharmacists, pharmacy
benefit managers, public and private insurers, patient organizations,
Federal and State Agencies, providers of continuing education for
healthcare professionals, and the public. A second public workshop is
being planned to solicit input on additional issues associated with a
move to mandatory prescriber education under a REMS, such as
operational and technical issues related to such a system and what
should be included in potential mandatory prescriber education.
DATES: The public workshop will be held on October 13, 2021, from 1
p.m. to 5 p.m. Eastern Time and October 14, 2021, from 1 p.m. to 4:05
p.m. Eastern Time. Submit either electronic or written comments on this
public workshop by December 3, 2021. See the SUPPLEMENTARY INFORMATION
section for registration date and information.
ADDRESSES: Due to the impact of the COVID-19 pandemic, these meetings
will be held virtually to help protect the public and limit the spread
of the virus.
You may submit comments as follows. Please note that late, untimely
filed comments will not be considered. Electronic comments must be
submitted on or before December 3, 2021. The <a href="https://www.regulations.gov">https://www.regulations.gov</a> electronic filing system will accept comments until
11:59 p.m. Eastern Time at the end of December 3, 2021. Comments
received by mail/hand delivery/courier (for written/paper submissions)
will be considered timely if they are postmarked or the delivery
service acceptance receipt is on or before that date.
Electronic Submissions
Submit electronic comments in the following way:
<bullet> Federal eRulemaking Portal: <a href="https://www.regulations.gov">https://www.regulations.gov</a>.
Follow the instructions for submitting comments. Comments submitted
electronically, including attachments, to <a href="https://www.regulations.gov">https://www.regulations.gov</a>
will be posted to the docket unchanged. Because your comment will be
made public, you are solely responsible for ensuring that your comment
does not include any confidential information that you or a third party
may not wish to be posted, such as medical information, your or anyone
else's Social Security number, or confidential business information,
such as a manufacturing process. Please note that if you include your
name, contact information, or other information that identifies you in
the body of your comments, that information will be posted on <a href="https://www.regulations.gov">https://www.regulations.gov</a>.
<bullet> If you want to submit a comment with confidential
information that you do not wish to be made available to the public,
submit the comment as a written/paper submission and in the manner
detailed (see ``Written/Paper Submissions'' and ``Instructions'').
Written/Paper Submissions
Submit written/paper submissions as follows:
<bullet> Mail/Hand Delivery/Courier (for written/paper
submissions): Dockets Management Staff (HFA-305), Food and Drug
Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852.
<bullet> For written/paper comments submitted to the Dockets
Management Staff, FDA will post your comment, as well as any
attachments, except for information submitted, marked and identified,
as confidential, if submitted as detailed in ``Instructions.''
Instructions: All submissions received must include the Docket No.
FDA-2021-N-0951 for ``Reconsidering Mandatory Opioid Prescriber
Education Through a Risk Evaluation and Mitigation Strategy (REMS) in
an Evolving Opioid Crisis.'' Comments filed and received in a timely
manner (see ADDRESSES) will be placed in the docket and, except for
those submitted as ``Confidential Submissions,'' publicly viewable at
<a href="https://www.regulations.gov">https://www.regulations.gov</a> or at the Dockets Management Staff between
9 a.m. and 4 p.m., Monday through Friday, 240-402-7500.
<bullet> Confidential Submissions--To submit a comment with
confidential information that you do not wish to be made publicly
available, submit your comments only as a written/paper submission. You
should submit two copies total. One copy will include the information
you claim to be confidential with a heading or cover note that states
``THIS DOCUMENT CONTAINS CONFIDENTIAL INFORMATION.'' The Agency will
review this copy, including the claimed confidential information, in
its consideration of comments. The
[[Page 50542]]
second copy, which will have the claimed confidential information
redacted/blacked out, will be available for public viewing and posted
on <a href="https://www.regulations.gov">https://www.regulations.gov</a>. Submit both copies to the Dockets
Management Staff. If you do not wish your name and contact information
to be made publicly available, you can provide this information on the
cover sheet and not in the body of your comments and you must identify
this information as ``confidential.'' Any information marked as
``confidential'' will not be disclosed except in accordance with 21 CFR
10.20 and other applicable disclosure law. For more information about
FDA's posting of comments to public dockets, see 80 FR 56469, September
18, 2015, or access the information at: <a href="https://www.govinfo.gov/content/pkg/FR-2015-09-18/pdf/2015-23389.pdf">https://www.govinfo.gov/content/pkg/FR-2015-09-18/pdf/2015-23389.pdf</a>.
Docket: For access to the docket to read background documents or
the electronic and written/paper comments received, go to <a href="https://www.regulations.gov">https://www.regulations.gov</a> and insert the docket number, found in brackets in
the heading of this document, into the ``Search'' box and follow the
prompts and/or go to the Dockets Management Staff, 5630 Fishers Lane,
Rm. 1061, Rockville, MD 20852, 240-402-7500.
FOR FURTHER INFORMATION CONTACT: Michie Hunt, Center for Drug
Evaluation and Research, Food and Drug Administration, 10903 New
Hampshire Ave., Bldg. 51, Rm. 6153, Silver Spring, MD 20993, 301-796-
3504, <a href="/cdn-cgi/l/email-protection#bad7d3d9d2d3df94d2cfd4cefadcdedb94d2d2c994ddd5cc"><span class="__cf_email__" data-cfemail="9ef3f7fdf6f7fbb0f6ebf0eadef8faffb0f6f6edb0f9f1e8">[email protected]</span></a>.
SUPPLEMENTARY INFORMATION:
I. Background
As FDA continues to work to address the opioid crisis, we are
reconsidering our current efforts to ensure prescriber education
regarding opioids is being delivered in a way that is as efficient and
effective as possible. As a part of this work, we are revisiting
whether there is a need for a mandatory form of prescriber education
linked to the prescribing of opioids. In 2012, FDA approved the
Extended Release/Long Acting (ER/LA) Risk Evaluation and Mitigation
Strategy (REMS), at the core of which was a requirement that sponsors
of ER/LA opioid analgesics make an education program available for
healthcare providers who prescribe ER/LA opioid analgesics (e.g.,
physicians, nurse practitioners, and physician assistants). The goal of
the ER/LA opioid analgesic REMS was to reduce serious adverse outcomes
resulting from inappropriate prescribing, misuse, and abuse of ER/LA
opioid analgesics while maintaining patient access to pain medications.
The adverse outcomes of concern included addiction, unintentional
overdose, and death.
While developing the REMS requirements, FDA considered whether the
education should be made mandatory for prescribers but decided against
making mandatory education a REMS requirement at the time. This was due
to concerns about placing an undue burden on the healthcare delivery
system, in part because the implementation of mandatory education
through the REMS might have required a restricted distribution system.
It is possible that given technological advances in the intervening
years, including broader implementation of e-prescribing for controlled
substances, there might be ways to lessen the burden associated with a
restricted distribution system, including potential negative impact on
patients who need opioids for pain management.
When the REMS was put in place in 2012, instead of mandatory
education, FDA required that ER/LA opioid manufacturers make the
training available to prescribers at no or nominal cost and that the
training be accessible in a variety of different formats. FDA also
recommended that the training be offered for continuing education (CE)
credit. The REMS as implemented requires the training to conform to a
blueprint (available at <a href="https://www.accessdata.fda.gov/drugsatfda_docs/rems/Opioid_analgesic_2018_09_18_FDA_Blueprint.pdf">https://www.accessdata.fda.gov/drugsatfda_docs/rems/Opioid_analgesic_2018_09_18_FDA_Blueprint.pdf</a>) developed by FDA
that contains a high-level outline of the core educational messages to
be included in the CE programs developed under the REMS. The initial
education program included general and product-specific information
about the ER/LA opioid analgesics; information on proper patient
selection for use of these drugs; guidance for safely initiating
therapy, modifying dosing, and discontinuing use of ER/LA opioid
analgesics; guidance for monitoring patients; and information for
counseling patients and caregivers about the safe use of these drugs.
After reviewing existing requirements and considering Advisory
Committee recommendations obtained in 2016 about the ER/LA REMS, in
2018 FDA expanded the REMS to include both immediate release (IR)
opioid analgesics and ER/LA opioid analgesics intended for use in an
outpatient setting. The content of the blueprint was redesigned to
contain principles of appropriate pain management, including the use of
alternatives to opioids for the treatment of pain; the basic elements
of addiction medicine; and the neurobiology, identification, and
management of opioid use disorder. The blueprint currently does not
include principles for managing opioid use disorder, including
treatment with buprenorphine. The revised Opioid Analgesic (OA) REMS
also expanded the prescriber audience and requires that the OA
manufacturers make training available to all members of the healthcare
team involved in the management of patients with pain, including nurses
and pharmacists. As with the ER/LA REMS, training under the OA REMS is
voluntary.
Cumulatively, from February 28, 2013, through May 15, 2021, there
have been 354,949 completers of REMS CE from the ER/LA REMS and the OA
REMS. For context, there were approximately 1 million prescribers of
opioid analgesics in 2019. In addition, although many public and
private entities have independently implemented their own education
programs and other interventions to encourage safe and effective
prescribing practices for opioid analgesics, there is no nationwide
standard. Therefore, these programs likely differ with regard to
content, focus, and duration.
Following the creation and expansion of the REMS and other efforts,
including the introduction of the Centers for Disease Control and
Prevention (CDC) Guideline for Prescribing Opioids for Chronic Pain in
2016,\1\ the estimated number of opioid analgesic prescriptions
dispensed per capita in the United States has been steadily declining
from a peak of 84 prescriptions per 100 residents in 2012 to 67
prescriptions per 100 residents in 2016; and 52 prescriptions per 100
residents in 2018. The rate dropped to 43 prescriptions per 100 U.S.
residents in 2020, reflecting levels not seen since the early 1990s (44
prescriptions per 100 U.S. residents in 1992).\2\ Despite this decrease
in dispensing, multiple studies have reported patients received more
opioid analgesic tablets than needed following surgical procedures.
FDA's systematic review of studies published prior to 2019 showed that
in articles reporting on the prescribing of excess tablets, 25 percent
to 98 percent of the total tablets prescribed were reported to be
excess, with most studies reporting that 50 percent to 70 percent of
tablets went unused.\3\ There are also
[[Page 50543]]
concerns about continued opioid analgesic prescribing to vulnerable
populations, such as children and adolescents following common dental
and minor surgical procedures.
---------------------------------------------------------------------------
\1\ Dowell, D., T.M. Haegerich, and R. Chou, ``CDC Guideline for
Prescribing Opioids for Chronic Pain--United States, 2016''. JAMA,
(2016) 315(15):1624-1645.
\2\ IQVIA Institute, ``National Prescription Audit'' extracted
March 2021, U.S. Census Bureau.
\3\ Mallama, C.A., C. Greene, A.A. Alexandridis, et al.
``Patient-Reported Opioid Analgesic Use After Discharge From
Surgical Procedures: A Systematic Review.'' (2021) Pain Medicine,
doi: 10.1093/pm/pnab244.
---------------------------------------------------------------------------
Despite this decline in opioid analgesic dispensing, overall
opioid-involved overdose deaths have risen sharply since 2012, with
opioids often seen in combination with other substances such as
cocaine, methamphetamine, and benzodiazepines.<SUP>4 5</SUP> This rise
has been driven primarily by a surge in deaths initially involving
heroin and then illicitly manufactured fentanyl and fentanyl analogues.
Although these overdose deaths largely involve illicit substances, many
users of illicit opioids are initially exposed to opioids through
nonmedical use of prescription opioids.\6\ Moreover, as of 2020,
prescription opioids were involved in more than 16,000 fatal overdoses
per year,\7\ higher than the number seen at the peak of opioid
analgesic dispensing in 2012.\8\
---------------------------------------------------------------------------
\4\ National Institute on Drug Abuse, ``Overdose Death Rates.''
(2021) (Available at: <a href="https://www.drugabuse.gov/drug-topics/trends-statistics/overdose-death-rates">https://www.drugabuse.gov/drug-topics/trends-statistics/overdose-death-rates</a>) (accessed August 20, 2021).
\5\ Mattson C.L., L.J. Tanz, K. Quinn, et al, ``Trends and
Geographic Patterns in Drug and Synthetic Opioid Overdose Deaths--
United States, 2013-2019.'' Morbidity and Mortality Weekly Report,
(2021) 70(6):202-207.
\6\ Compton, W.M., C.M. Jones, and G.T. Baldwin, ``Relationship
Between Nonmedical Prescription-Opioid Use and Heroin Use.'' New
England Journal of Medicine, (2016) 374:154-163.
\7\ Ahmad, F.B., L.M. Rossen, and P. Sutton, ``Provisional Drug
Overdose Death Counts.'' National Center for Health Statistics,
2021. (Available at: <a href="https://www.cdc.gov/nchs/nvss/vsrr/drug-overdose-data.htm">https://www.cdc.gov/nchs/nvss/vsrr/drug-overdose-data.htm</a>) (accessed 8/20/2021).
\8\ National Institute on Drug Abuse, ``Overdose Death Rates.''
January 29, 2021. (Available at: <a href="https://www.drugabuse.gov/drug-topics/trends-statistics/overdose-death-rates">https://www.drugabuse.gov/drug-topics/trends-statistics/overdose-death-rates</a>).
---------------------------------------------------------------------------
Against this background of a complex and intensifying crisis, FDA
is reconsidering the need for mandatory prescriber training through a
REMS and seeks input from stakeholders about the aspects of the opioid
crisis that mandatory training through such a REMS could potentially
mitigate. In light of the many available education programs and the
lack of a nationwide standard, FDA is exploring the value of a single
source for education on the appropriate use of opioids, on the risks of
opioid abuse and misuse, and on the treatment of opioid use disorder to
address multiple needs and reduce the burden on prescribers.
II. Topics for Discussion at the Public Workshop
1. How could mandatory prescriber education through a REMS improve
appropriate opioid prescribing, pain management, and the treatment of
opioid use disorder?
a. Please specifically discuss the value of such a system in light
of existing continuing education requirements, the wide array of
available educational programs (including currently available OA REMS
educational offerings), and other interventions by Federal Agencies,
States, healthcare systems, retail pharmacies, payers, pharmacy benefit
managers, and other public and private organizations. Could mandatory
education under a REMS make prescriber education more consistent,
efficient, and effective?
b. Please specifically discuss how a mandatory REMS educational
program could address the needs for prescriber education on the
overprescribing of opioids for acute pain.
c. Please specifically discuss how a mandatory REMS educational
program could address the needs for prescriber education on the
treatment of opioid use disorder.
2. What are the important core competencies, knowledge gaps,
clinical challenges, or misunderstandings among practitioners that
could be addressed through mandatory education under a REMS to help
improve patient outcomes and mitigate the current crisis?
a. Please comment specifically on any key knowledge gaps or core
competencies related to screening, diagnosis, or treatment of opioid
use disorder or substance use disorder that should be incorporated into
mandatory education for opioid prescribers.
3. If FDA were to implement a mandatory prescriber education
program, please discuss what appropriate program goals might be. How
could we measure the impacts of such a program and determine whether it
is meeting its goals?
4. Regarding the implementation of such a mandatory REMS
educational system:
a. Please discuss challenges you foresee in the implementation of a
mandatory REMS educational system.
b. What can we learn about the implementation of prescriber
education from existing educational programs in pain management, in
opioid risk reduction, and in the treatment of opioid use disorder?
5. What could be unintended consequences of mandatory opioid
prescriber education through a REMS and are there ways to identify and
address them?
Although not specifically discussed at this Public Workshop, FDA is
interested in obtaining input on additional issues, including:
a. The continuing education delivery approaches, methods, and
information technology platforms that should be considered to maximize
the acceptability and effectiveness of mandatory prescriber education.
b. Any technological advances since 2012 that would make the
delivery of mandatory training more efficient and reduce burden on the
healthcare system.
III. Participating in the Public Workshop
Registration: To register for the public workshop, please visit the
following website: <a href="http://events.constantcontact.com/register/event?llr=4fyj4myab&oeidk=a07eifbycnsfd5b6b1f">http://events.constantcontact.com/register/event?llr=4fyj4myab&oeidk=a07eifbycnsfd5b6b1f</a>. Please provide complete
contact information for each attendee, including name, title,
affiliation, address, email, and telephone.
Registration is free. Persons interested in attending this public
workshop must register by 4:05 p.m. Eastern Time on October 14, 2021.
Registrants will receive confirmation when they have been accepted.
Registered participants will be sent technical system requirements in
advance of the event. We recommend that you review these technical
system requirements prior to joining the virtual public workshop. The
workshop will be recorded, and the recording will be available after
the workshop at <a href="https://healthpolicy.duke.edu/events/fda-public-workshop-opioid-prescriber-education">https://healthpolicy.duke.edu/events/fda-public-workshop-opioid-prescriber-education</a>.
There will be live closed captioning for this event. If you need
other special accommodations due to a disability, please contact Michie
Hunt (see FOR FURTHER INFORMATION CONTACT) no later than October 4,
2021, or the Duke-Margolis Center for Health Policy at
<a href="/cdn-cgi/l/email-protection#701d1102171f1c19031506151e04033014051b155e151405"><span class="__cf_email__" data-cfemail="a4c9c5d6c3cbc8cdd7c1d2c1cad0d7e4c0d1cfc18ac1c0d1">[email protected]</span></a>.
FDA has verified the website addresses in this document, as of the
date this document publishes in the Federal Register, but websites are
subject to change over time.
Dated: September 2, 2021.
Lauren K. Roth,
Acting Principal Associate Commissioner for Policy.
[FR Doc. 2021-19437 Filed 9-8-21; 8:45 am]
BILLING CODE 4164-01-P
</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>Indexed from Federal Register on September 9, 2021.
This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.